TABLE 2.
Characteristics of patients included in the trials
| Study | CAR‐T arm/SOC arm | Patients, n | Age, years, median (range) | Age ≥65 years, n (%) | Sex, male, n (%) | High IPI, n (%) | High‐grade LBCL (IRC), n (%) | Follow‐up, months, median (range) | CAR‐T – bridging chemotherapy, n/N (%) | Cross over to CAR‐T among SOC arm, n/N (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Locke et al. 15 2021 (ZUMA‐7) |
Axi‐cel 2–3 salvage+ASCT |
180 179 |
58 (21–80) 60 (26–81) |
51 (28) 58 (32) |
110 (61) 127 (71) |
sAAIPI 2–3 ‐ 82 (46) sAAIPI 2–3 ‐ 79 (44) |
17 (9) 15 (8) |
24.9 | None | 100/179 (56) |
| Bishop et al. 16 2021 (BELINDA) |
Tisa‐cel 2–3 salvage+ASCT |
162 160 |
59.5 (19–79) 58 (19–77) |
54 (33) 46 (29 |
103 (63.6) 98 (61.2) |
IPI score ≥2106 (65) IPI score ≥2 92 (57) |
39 (24) 27 (17) |
10 (2.9–23.2) | 134/162 (83) | 81/160 (51) |
| Kamdar et al. 14 2021 (TRANSFORM) |
Liso‐cel 3 salvage+ASCT |
92 92 |
60 (20–74) 58 (26–75) |
36 (39) 27 (29) |
44 (48) 61 (66) |
sAAIPI 2–3 ‐ 36 (39) sAAIPI 2–3 ‐ 37 (40) |
22 (24) 21 (23) |
6.2 (0.9–20) | 58/92 (63) | 50/92 (54) |
Abbreviations: ASCT, Autologous stem cell transplantation; CAR‐T, chimeric antigen receptor T‐cell therapy; sAAIPI, second‐line age‐adjusted International Prognostic Index; SOC, standard of care.